Allogene Therapeutics (ALLO) announced that Earl Douglas has been appointed as General Counsel. Douglas will oversee all aspects of the Company’s legal function and serve as a member of the Leadership Team. Prior to Allogene, Douglas served as General Counsel for Applied Molecular Transport (AMTI), a clinical-stage biopharmaceutical company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALLO:
- Allogene Therapeutics reports Q2 EPS (53c), consensus (59c)
- Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
- ‘Too Cheap to Ignore’: J.P. Morgan Says These 2 Stocks Under $10 Could Double Your Money
- ALLO Upcoming Earnings Report: What to Expect?
- Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023